Emerg­ing from stealth mode, Aard­vark rounds up enough cash to put its lead drug through Prad­er-Willi PhII

When Aard­vark Ther­a­peu­tics CEO Tien Lee start­ed his work on the biotech’s lead can­di­date, ap­petite sup­pres­sion was the goal for the small mol­e­cule. Soon af­ter …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER